NeurologyNarcolepsy pill brings wakefulness to normal levels in two trials
NEJM has published two phase 3 trials of oveporexton, the first orexin agonist, showing big cuts in cataplexy and normal wakefulness scores, with insomnia and bladder effects common.
9 September 2026